TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Research on the Efficacy and Safety of East-West Collaborative Treatment Using NSAIDs and BV on Chronic Cervical Pain; A Randomized, Controlled, Parallel, Pilot Study
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of east-west collaborative treatment using bee venom acupuncture and NSAIDs on pain intensity, functional status and quality of life of patients with chronic cervicalgia


Options:
A: Arm Label: Deep dry needling; Type: ACTIVE_COMPARATOR; Interventions: Other: Group 1. Deep dry needling | Arm Label: muscle stretch; Type: OTHER; Interventions: Other: Group 1. Deep dry needling, Other: group 2. Passive analitical stretch (performed in both groups) | Intervention Type: OTHER; Name: Group 1. Deep dry needling; Assigned to Arm(s): Deep dry needling, muscle stretch | Intervention Type: OTHER; Name: group 2. Passive analitical stretch (performed in both groups); Assigned to Arm(s): muscle stretch
B: Arm Label: Bee Venom Acupuncture; Type: EXPERIMENTAL; Interventions: Procedure: Bee Venom Acupuncture | Arm Label: Loxoprofen; Type: EXPERIMENTAL; Interventions: Drug: Loxoprofen | Arm Label: EWCT : Bee Venom Acupucture and Loxoprofen; Type: EXPERIMENTAL; Interventions: Procedure: Bee Venom Acupuncture, Drug: Loxoprofen | Intervention Type: PROCEDURE; Name: Bee Venom Acupuncture; Assigned to Arm(s): Bee Venom Acupuncture, EWCT : Bee Venom Acupucture and Loxoprofen | Intervention Type: DRUG; Name: Loxoprofen; Assigned to Arm(s): EWCT : Bee Venom Acupucture and Loxoprofen, Loxoprofen
C: Arm Label: Dry needling (deep); Type: EXPERIMENTAL; Interventions: Procedure: Dry needling | Arm Label: Dry needling (superficial); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Dry needling | Intervention Type: PROCEDURE; Name: Dry needling; Assigned to Arm(s): Dry needling (deep), Dry needling (superficial)
D: Arm Label: medication(Zaltoprofen); Type: ACTIVE_COMPARATOR; Interventions: Procedure: acupuncture | Arm Label: Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Procedure: acupuncture | Arm Label: Zalprofen plus Acupuncture; Type: ACTIVE_COMPARATOR; Interventions: Procedure: acupuncture | Intervention Type: PROCEDURE; Name: acupuncture; Assigned to Arm(s): Acupuncture, Zalprofen plus Acupuncture, medication(Zaltoprofen)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Adductor Canal Blockade vs Femoral Nerve Blockade on Muscle Strength, Mobility and Pain in Patients With Severe Pain After Total Knee Arthroplasty
Brief Summary: The purpose of the study is to compare the effect of a Adductor Canal Blockade (ACB) vs a Femoral Nerve Blockade (FNB), on muscle strength, mobility and pain in patients with severe pain (VAS pain score \> 60) after Total Knee Arthroplasty (TKA.


Options:
A: Arm Label: Active FNB, placebo ACB; Type: EXPERIMENTAL; Interventions: Drug: Ropivacaine, Drug: Placebo | Arm Label: Active ACB, placebo FNB; Type: EXPERIMENTAL; Interventions: Drug: Ropivacaine, Drug: Placebo | Intervention Type: DRUG; Name: Ropivacaine; Assigned to Arm(s): Active ACB, placebo FNB, Active FNB, placebo ACB | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Active ACB, placebo FNB, Active FNB, placebo ACB
B: Arm Label: Femoral nerve block; Type: EXPERIMENTAL; Interventions: Procedure: Sono guided nerve block | Arm Label: Adductor canal block; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Sono guided nerve block | Intervention Type: PROCEDURE; Name: Sono guided nerve block; Assigned to Arm(s): Adductor canal block, Femoral nerve block
C: Arm Label: Adductor-Canal-Blockade; Type: EXPERIMENTAL; Interventions: Procedure: Adductor-Canal-Blockade | Arm Label: Adductor-Canal-blockade with saline; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Adductor-Canal-blockade with saline | Intervention Type: PROCEDURE; Name: Adductor-Canal-Blockade; Assigned to Arm(s): Adductor-Canal-Blockade | Intervention Type: PROCEDURE; Name: Adductor-Canal-blockade with saline; Assigned to Arm(s): Adductor-Canal-blockade with saline
D: Arm Label: Epidural Catheter without Adductor Canal Nerve Block Catheter; Type: SHAM_COMPARATOR; Interventions: Device: Adductor Canal Nerve Block Sham Catheter, Drug: Bupivacaine | Arm Label: Epidural Catheter with Adductor Canal Nerve Block Catheter; Type: EXPERIMENTAL; Interventions: Device: Adductor Canal Nerve Block Catheter, Drug: Bupivacaine | Intervention Type: DEVICE; Name: Adductor Canal Nerve Block Catheter; Assigned to Arm(s): Epidural Catheter with Adductor Canal Nerve Block Catheter | Intervention Type: DEVICE; Name: Adductor Canal Nerve Block Sham Catheter; Assigned to Arm(s): Epidural Catheter without Adductor Canal Nerve Block Catheter | Intervention Type: DRUG; Name: Bupivacaine; Assigned to Arm(s): Epidural Catheter with Adductor Canal Nerve Block Catheter, Epidural Catheter without Adductor Canal Nerve Block Catheter

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Study Investigating Optimal Duration of Indwelling Urinary Catheter Following Infraperitoneal Colorectal Surgery and Role of Postoperative Alpha Blockade
Brief Summary: There is no general agreement about the optimal duration of postoperative urinary drainage, with relevant literature reporting durations ranging from 1 to 10 days. The available research supporting the routine use of prolonged catheterization is limited and studies investigating early removal following infraperitoneal colorectal surgery have largely been underpowered to form valid practice conclusions. The aim of the investigators study is to determine whether a postoperative colorectal patient can safely have an indwelling catheter removed on postoperative day one (24 hours following surgery) with the addition of a study medication (prazosin), without a statistically significant difference in the incidence of urinary retention compared to the standard, accepted approach of delayed removal (72 hours postoperatively). Patients undergoing laparoscopic and open pelvic colorectal surgery below the peritoneal reflection for both benign and malignant conditions will be randomized into two groups: group one will have the catheter removed on postoperative day 3 (72 hours postoperatively) Group 2 will have a dose of the alpha-blocker prazosin given 6 hours prior to catheter removal and will have the urinary catheter removed on postoperative day 1 (24 hours postoperatively).


Options:
A: Arm Label: 24 hour postop catheter removal; Type: EXPERIMENTAL; Interventions: Drug: Prazosin given 6 hours prior to catheter removal in the 24 hour group | Arm Label: 72 hour postoperative catheter removal; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Prazosin given 6 hours prior to catheter removal in the 24 hour group; Assigned to Arm(s): 24 hour postop catheter removal
B: Arm Label: Early (within 48 hours of surgery); Type: N/A; Interventions: N/A | Arm Label: Late (6 hours after epidural removal); Type: N/A; Interventions: N/A
C: Arm Label: voiding trial 4 hours post-op; Type: EXPERIMENTAL; Interventions: Procedure: Retrograde voiding trial | Arm Label: voiding trial post-op day 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Retrograde voiding trial | Intervention Type: PROCEDURE; Name: Retrograde voiding trial; Assigned to Arm(s): voiding trial 4 hours post-op, voiding trial post-op day 1
D: Arm Label: Tamsulosin 0.4mg; Type: EXPERIMENTAL; Interventions: Drug: tamsulosin 0.4mg | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: No medication | Intervention Type: DRUG; Name: tamsulosin 0.4mg; Assigned to Arm(s): Tamsulosin 0.4mg | Intervention Type: OTHER; Name: No medication; Assigned to Arm(s): Control

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized,Double-blind Trial Comparing the Effects of a Rivaroxaban Regimen During the First 30 Days,Versus Aspirin for the Acute Treatment of TIA or Minor Stroke
Brief Summary: Transient ischemic attack (TIA) or minor ischemic stroke has a high risk of early recurrent stroke. As the golden standard, aspirin effect modestly on acute ischemic stroke, and slightly increase the risk of intracerebral hemorrhage. Recently, rivaroxaban, a new oral anticoagulant, is proved to be as effective as traditional anticoagulants, while carrying significantly less risk of intracranial hemorrhage.

The TRACE trial is a randomized, double-blind, multicenter, controlled clinical trial in China. The investigators will assess the hypothesis that a 30-days rivaroxaban regimen is superior to aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.


Options:
A: Arm Label: Clopidogrel-aspirin; Type: EXPERIMENTAL; Interventions: Drug: Clopidogrel-aspirin | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Clopidogrel-aspirin; Assigned to Arm(s): Clopidogrel-aspirin
B: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin
C: Arm Label: aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin, Drug: placebo | Arm Label: Rivaroxaban 5mg; Type: EXPERIMENTAL; Interventions: Drug: rivaroxaban, Drug: placebo | Arm Label: rivaroxaban 10mg; Type: EXPERIMENTAL; Interventions: Drug: rivaroxaban, Drug: placebo | Intervention Type: DRUG; Name: rivaroxaban; Assigned to Arm(s): Rivaroxaban 5mg, rivaroxaban 10mg | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): aspirin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Rivaroxaban 5mg, aspirin, rivaroxaban 10mg
D: Arm Label: dabigatran etexilate 110 or 150 mg; Type: EXPERIMENTAL; Interventions: Drug: optional ASA as comedication, Drug: placebo to ASA, Drug: dabigatran etexilate | Arm Label: ASA 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo to optional ASA as comedication, Drug: placebo to dabigatran etexilate, Drug: ASA 100 mg | Intervention Type: DRUG; Name: optional ASA as comedication; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg | Intervention Type: DRUG; Name: placebo to ASA; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg | Intervention Type: DRUG; Name: placebo to optional ASA as comedication; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: placebo to dabigatran etexilate; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: ASA 100 mg; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of Wound Closure Techniques in Primary Total Knee Arthroplasty Using SPY Intra-operative Angiography
Brief Summary: This study will assess which of the three most common methods of wound closure in primary total knee arthroplasty (staples, interrupted vertical mattress, or running subcuticular suture) provide the best wound vascular perfusion. This can be achieve by using SPY intra-operative vascular angiography, which is commonly used in clinical practice to assess perfusion of wound closure at the clinic. By understanding the differences in perfusion afforded by different closure techniques, surgeons will then be able to select the technique that optimizes this parameter so as to avoid complications such as tissue necrosis, wound dehiscence, or infection.


Options:
A: Arm Label: Continuous intradermic stitch; Type: EXPERIMENTAL; Interventions: Procedure: Continuous intradermic stitch | Arm Label: Separated stitches; Type: SHAM_COMPARATOR; Interventions: Procedure: Separated stitches | Intervention Type: PROCEDURE; Name: Continuous intradermic stitch; Assigned to Arm(s): Continuous intradermic stitch | Intervention Type: PROCEDURE; Name: Separated stitches; Assigned to Arm(s): Separated stitches
B: Arm Label: Chinese Silk Suture; Type: ACTIVE_COMPARATOR; Interventions: Device: silk suture | Arm Label: VICRYL* Plus Suture; Type: EXPERIMENTAL; Interventions: Device: VICRYL* Plus suture | Intervention Type: DEVICE; Name: silk suture; Assigned to Arm(s): Chinese Silk Suture | Intervention Type: DEVICE; Name: VICRYL* Plus suture; Assigned to Arm(s): VICRYL* Plus Suture
C: Arm Label: Staple Closure; Type: EXPERIMENTAL; Interventions: Procedure: Staple Closure | Arm Label: Running Subcuticular Closure; Type: EXPERIMENTAL; Interventions: Procedure: Running Subcuticular Closure | Arm Label: Vertical Mattress Closure; Type: EXPERIMENTAL; Interventions: Procedure: Vertical Mattress Closure | Intervention Type: PROCEDURE; Name: Staple Closure; Assigned to Arm(s): Staple Closure | Intervention Type: PROCEDURE; Name: Vertical Mattress Closure; Assigned to Arm(s): Vertical Mattress Closure | Intervention Type: PROCEDURE; Name: Running Subcuticular Closure; Assigned to Arm(s): Running Subcuticular Closure
D: Arm Label: Stainless Steel Staples; Type: ACTIVE_COMPARATOR; Interventions: Device: Stainless steel staples | Arm Label: 4-0 monofilament Sutures; Type: EXPERIMENTAL; Interventions: Device: 4-0 monofilament suture | Intervention Type: DEVICE; Name: 4-0 monofilament suture; Assigned to Arm(s): 4-0 monofilament Sutures | Intervention Type: DEVICE; Name: Stainless steel staples; Assigned to Arm(s): Stainless Steel Staples

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase III Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy
Brief Summary: This study is a phase III, multi-centre study of olaparib in combination with paclitaxel, compared with placebo in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy. Patients will be from China, Japan , Korea and Taiwan.


Options:
A: Arm Label: A 850; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: B 425; Type: EXPERIMENTAL; Interventions: Drug: apatinib tablet | Arm Label: C pla; Type: PLACEBO_COMPARATOR; Interventions: Drug: apatinib tablet | Intervention Type: DRUG; Name: apatinib tablet; Assigned to Arm(s): A 850, B 425, C pla
B: Arm Label: Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel; Type: EXPERIMENTAL; Interventions: Biological: Ramucirumab (IMC-1211B) DP, Drug: Paclitaxel | Arm Label: Placebo and Paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Paclitaxel | Intervention Type: BIOLOGICAL; Name: Ramucirumab (IMC-1211B) DP; Assigned to Arm(s): Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and Paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Placebo and Paclitaxel, Ramucirumab (IMC-1211B) Drug Product (DP) and Paclitaxel
C: Arm Label: Olaparib+ paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Paclitaxel | Arm Label: Placebo+paclitaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Placebo | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib+ paclitaxel | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Olaparib+ paclitaxel, Placebo+paclitaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+paclitaxel
D: Arm Label: Trastuzumab, Fluoropyrimidine, Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: Trastuzumab, Drug: Fluorouracil, Drug: Cisplatin, Drug: Capecitabine | Arm Label: Fluoropyrimidine, Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluorouracil, Drug: Cisplatin, Drug: Capecitabine | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Fluorouracil; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Fluoropyrimidine, Cisplatin, Trastuzumab, Fluoropyrimidine, Cisplatin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-institutional Trial Comparing Clinical Outcomes Following Low- vs. Standard-dose Abdominal CT as the First-line Imaging Test in Adolescents and Young Adults With Suspected Acute Appendicitis
Brief Summary: To determine whether low-dose (LD) CT is noninferior to standard-dose (SD) computed tomography (CT) as the first-line imaging test in adolescents and young adults in regard to negative appendectomy rate (NAR).


Options:
A: Arm Label: Low-dose CT; Type: EXPERIMENTAL; Interventions: Radiation: Diagnostic CT | Arm Label: Standard-dose CT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Diagnostic CT | Intervention Type: RADIATION; Name: Diagnostic CT; Assigned to Arm(s): Low-dose CT | Intervention Type: RADIATION; Name: Diagnostic CT; Assigned to Arm(s): Standard-dose CT
B: Arm Label: Diagnostic imaging; Type: EXPERIMENTAL; Interventions: Procedure: Diagnostic imaging | Arm Label: Repeat examination after observation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Diagnostic imaging | Intervention Type: PROCEDURE; Name: Diagnostic imaging; Assigned to Arm(s): Diagnostic imaging, Repeat examination after observation
C: Arm Label: Operative treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Appendicectomy | Arm Label: Antibiotic treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ertapenem | Intervention Type: PROCEDURE; Name: Appendicectomy; Assigned to Arm(s): Operative treatment | Intervention Type: DRUG; Name: Ertapenem; Assigned to Arm(s): Antibiotic treatment
D: Arm Label: Low-dose CT; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Diagnostic CT with low-dose radiation | Arm Label: Standard-dose CT; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Diagnostic CT with standard-dose radiation | Intervention Type: DIAGNOSTIC_TEST; Name: Diagnostic CT with low-dose radiation; Assigned to Arm(s): Low-dose CT | Intervention Type: DIAGNOSTIC_TEST; Name: Diagnostic CT with standard-dose radiation; Assigned to Arm(s): Standard-dose CT

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-institutional Trial Comparing Clinical Outcomes Following Low- vs. Standard-dose Abdominal CT as the First-line Imaging Test in Adolescents and Young Adults With Suspected Acute Appendicitis
Brief Summary: To determine whether low-dose (LD) CT is noninferior to standard-dose (SD) computed tomography (CT) as the first-line imaging test in adolescents and young adults in regard to negative appendectomy rate (NAR).


Options:
A: Arm Label: Antibiotics Therapy Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin | Arm Label: Appendectomy Arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Appendectomy | Intervention Type: DRUG; Name: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin; Assigned to Arm(s): Antibiotics Therapy Arm | Intervention Type: PROCEDURE; Name: Appendectomy; Assigned to Arm(s): Appendectomy Arm
B: Arm Label: Low-dose CT; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Diagnostic CT with low-dose radiation | Arm Label: Standard-dose CT; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Diagnostic CT with standard-dose radiation | Intervention Type: DIAGNOSTIC_TEST; Name: Diagnostic CT with low-dose radiation; Assigned to Arm(s): Low-dose CT | Intervention Type: DIAGNOSTIC_TEST; Name: Diagnostic CT with standard-dose radiation; Assigned to Arm(s): Standard-dose CT
C: Arm Label: Low-dose CT; Type: EXPERIMENTAL; Interventions: Radiation: Diagnostic CT | Arm Label: Standard-dose CT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Diagnostic CT | Intervention Type: RADIATION; Name: Diagnostic CT; Assigned to Arm(s): Low-dose CT | Intervention Type: RADIATION; Name: Diagnostic CT; Assigned to Arm(s): Standard-dose CT
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: appendectomy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: amoxicillin/clavulanate potassium | Intervention Type: DRUG; Name: amoxicillin/clavulanate potassium; Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: appendectomy; Assigned to Arm(s): A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Hypocholesterolaemic and Prebiotic Effects of a Whole-grain Oat-based Breakfast Cereal in a Cardio-metabolic 'at Risk' Population
Brief Summary: Intake of whole grain cereals has been associated with reducing the risk of hyperlipidaemia and heart disease, however the mechanisms by which oats or oat fractions exert this effect is not totally clear. Furthermore, several large epidemiological studies and a number of recent meta-analyses of nutritional interventions have reported a positive association between increased whole grain intake and reduced risk of developing a range of chronic diseases. Recognising the important role of the gut microbiota in metabolism and metabolic disease risk, we examined the impact of whole grain oats on the human gut microbiota and cardio-metabolic risk factors.

The main aims of this human study is to determine the effectiveness of a low GI whole grain oats breakfast cereal compared to a high GI, refined breakfast cereal to beneficially modulate gut microbiota and its metabolic output, plasma lipids, gut satiety hormones and inflammation markers in an at risk of cardio-metabolic disease population


Options:
A: Arm Label: Usual care group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: diet group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 50g-ONOG plus diet group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: organic naked oat with whole germ (ONOG) | Arm Label: 100g-ONOG plus diet group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: organic naked oat with whole germ (ONOG) | Intervention Type: DIETARY_SUPPLEMENT; Name: organic naked oat with whole germ (ONOG); Assigned to Arm(s): 100g-ONOG plus diet group, 50g-ONOG plus diet group
B: Arm Label: Low Glycemic Index Diet; Type: EXPERIMENTAL; Interventions: Other: Low Glycemic Index diet | Arm Label: High Fiber Diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High Cereal Fibre Diets | Intervention Type: OTHER; Name: Low Glycemic Index diet; Assigned to Arm(s): Low Glycemic Index Diet | Intervention Type: OTHER; Name: High Cereal Fibre Diets; Assigned to Arm(s): High Fiber Diet
C: Arm Label: Wholegrain cereal oats; Type: EXPERIMENTAL; Interventions: Dietary Supplement: wholegrain cereals oats (WGO) | Arm Label: Non wholegrain cereals; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Non wholegrain cereals | Intervention Type: DIETARY_SUPPLEMENT; Name: wholegrain cereals oats (WGO); Assigned to Arm(s): Wholegrain cereal oats | Intervention Type: DIETARY_SUPPLEMENT; Name: Non wholegrain cereals; Assigned to Arm(s): Non wholegrain cereals
D: Intervention Type: BEHAVIORAL; Name: Whole Grain Foods; Assigned to Arm(s): N/A

Answer: C